<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00942006</url>
  </required_header>
  <id_info>
    <org_study_id>LNB-doxy-ceftriaxone</org_study_id>
    <nct_id>NCT00942006</nct_id>
  </id_info>
  <brief_title>Doxycycline and Ceftriaxone in Suspected Early Lyme Neuroborreliosis</brief_title>
  <official_title>Doxycycline and Ceftriaxone in Patients With Suspected Early Lyme Neuroborreliosis and Normal CSF Cell Count.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will compare doxycycline and ceftriaxone in treatment of patients with
      suspected early Lyme neuroborreliosis and normal CSF cell count. The study hypothesis is that
      the efficacy and adverse effects of both antibiotics are comparable.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective sequelae and post-treatment subjective symptoms in patients treated for suspected early Lyme neuroborreliosis with normal CSF cell count with doxycycline or ceftriaxone for 14 days.</measure>
    <time_frame>1 year follow-up</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Suspected Early Lyme Neuroborreliosis</condition>
  <arm_group>
    <arm_group_label>LNB-doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LNB-ceftriaxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
    <description>100 mg bid, 14 days</description>
    <arm_group_label>LNB-doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <description>2g x 1 iv, 14 days</description>
    <arm_group_label>LNB-ceftriaxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;15 years

          -  erythema migrans in 4 months period before neurologic symptoms

          -  normal CSF cell count

          -  absence of more defined clinical symptoms or signs for CNS involvement (radicular
             pain, meningeal signs, peripheral facial palsy).

        Exclusion Criteria:

          -  pregnancy

          -  lactation

          -  allergy on doxycycline and ceftriaxone

          -  immune deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franc Strle, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarina Ogrinc, MD PhD</last_name>
    <phone>+386 1 522 4217</phone>
    <email>katarina.ogrinc1@guest.arnes.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franc Strle, PhD MD</last_name>
    <phone>+386 1 522 2110</phone>
    <email>franc.strle@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC Ljubljana, Department of Infectious Diseases</name>
      <address>
        <city>Ljubljana</city>
        <zip>1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2009</study_first_submitted>
  <study_first_submitted_qc>July 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2009</study_first_posted>
  <last_update_submitted>July 17, 2009</last_update_submitted>
  <last_update_submitted_qc>July 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Katarina Ogrinc MD PhD</name_title>
    <organization>UMC Ljubljana</organization>
  </responsible_party>
  <keyword>Lyme neuroborreliosis</keyword>
  <keyword>Lyme borreliosis</keyword>
  <keyword>erythema migrans</keyword>
  <keyword>doxycycline treatment</keyword>
  <keyword>ceftriaxone treatment</keyword>
  <keyword>outcome</keyword>
  <keyword>subjective symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lyme Neuroborreliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

